Translational Applications of New Insights into Immunoreceptor Signalling

White blood cells carry surface receptors that, when triggered by the wrong targets, can spark autoimmune disease—and researchers are now designing antibody-based therapies to block that process. This matters because autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis arise when immune receptors mistakenly recognise the body’s own proteins as foreign and launch an attack. The fundamental gap in knowledge is exactly how these receptors reorganise on the cell surface to switch on immune pathways. Without that mechanistic understanding, designing drugs that precisely control the response remains guesswork. If the research succeeds, it could produce a new class of antibody-based therapies—receptor agonists that mimic natural triggering but are engineered to dampen rather than amplify harmful immune reactions. These would be drug-like molecules, not just research tools, and could offer more targeted treatments for autoimmune patients, reducing reliance on broad immunosuppressants that leave people vulnerable to infection. This project is primarily curiosity-driven fundamental science into immunoreceptor signalling. But the group is explicitly working toward translational applications: a clear mechanistic picture of how receptors trigger immune pathways is the necessary foundation for rational antibody design. Past fundamental discoveries in receptor biology have already yielded blockbuster antibody drugs; this work aims to extend that track record into autoimmune disease.